Physician profile
Paul Jordan
NPI 1801813613
$2,888.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $718 · 2021: $491 · 2023: $76.13 · 2024: $50.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.35 | 2019-2021 | |
| Pfizer INC. | $430.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.78 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $358.95 | 2019-2021 | |
| Janssen Biotech, INC. | $245.07 | 2019-2021 | |
| Boston Scientific Corporation | $142.81 | 2019-2023 | Exalt Model D |
| Ucb, INC. | $63.67 | 2019-2020 | |
| Erbe USA INC | $50.00 | 2024 | |
| Intercept Pharmaceuticals, INC. | $44.82 | 2019 | |
| Shire North American Group INC | $42.40 | 2019 | |
| Dynavax Technologies Corporation | $39.14 | 2019-2020 | |
| Gilead Sciences, INC. | $37.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.83 | 2019-2021 | |
| Braintree Laboratories, INC. | $27.45 | 2020-2021 | |
| Cook Medical LLC | $25.32 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $15.21 | 2019 | |
| Allergan, INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.